Genen­tech-part­nered Novome lands $43.5M to push gas­troin­testi­nal drug through mid-stage study

A biotech with con­nec­tions to Roche’s Genen­tech has now land­ed its newest cash in­fu­sion.

Mi­cro­bio­me out­fit Novome Biotech­nolo­gies said Tues­day that it has now se­cured $43.5 mil­lion in new fi­nanc­ing via a Se­ries B round. The funds, ac­cord­ing to the com­pa­ny, will be used to ad­vance its lead can­di­date through an on­go­ing Phase IIa — and ad­vance oth­er can­di­dates for a po­ten­tial in­di­ca­tion in in­flam­ma­to­ry bow­el dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER